Baidu
map

Radiology:对于急性缺血性卒中患者,这一影像学指标可提示预后!

2022-01-15 shaosai MedSci原创

在急性缺血性卒中(AIS)中,由于局部脑血流的减少,脑组织局部静脉氧饱和度(SvO2)下降。

在急性缺血性卒中(AIS)中,由于局部脑血流的减少,脑组织局部静脉氧饱和度(SvO2)下降。 脑功能对氧饱和度的变化特别敏感,如果发生长期缺氧发生不可逆损伤。氧饱和度的降低可以作为梗死的主要预测因素之一

多项研究表明,不对称皮质静脉(APCVs)与氧饱和度下降有关。以往关于氧饱和度定量分析的研究仅限于AIS的预处理,对于APCVs与神经系统预后的关系则仅限于定性分析或短期NIHSS评分的变化。到目前为止,还未有关于治疗前后氧饱和度变化的可靠定量评估。

近日,发表在Radiology杂志的一项研究应用QSM纵向量化急性缺血性脑卒中脑部MRI的SvO2,并对其在标准化治疗后2周随访的变化进行定量分析,并进一步评估SvO2对临床预后的影响,为临床早期评估AIS提供了有价值的影像学技术支持

2016年至2020年期间,本研究回顾性地纳入了在症状发生后24小时内和治疗后2周内接受脑部MRI扫描的AIS患者。使用QSM对APCV的SvO2进行了量化。独立样本t检验用于比较有和没有APCVs的患者的SvO2。用配对样本t检验来评估SvO2的动态变化。Pearson和Spearman相关分析用于探讨SvO2动态变化与低灌注、NIHSS评分变化和90天改良Rankin量表(mRS)评分之间的关系。采用独立样本t检验来比较不同临床预后和结果亚组之间的SvO2动态变化。

73名患者中的39名(平均年龄70岁±10[标准差];49名男性)在入院时检测到APCV,35名患者在2周的随访MRI中消失。39名患者的平均SvO2从35.0% ± 5.8增加到64.5% ± 10.0(P < .001)。对于35名APCV消失的患者,SvO2的动态变化与NIHSS评分的变化(r = -0.37, R2 = 0.19, P = .03)呈负相关90天mRS评分(r = -0.54, R2 = 0.27, P = . 001)90天疗效好的亚组(n = 19)的SvO2动态变化大于90天疗效差的亚组(n = 16)(平均,34.5% ± 5.8 vs 29.7% ± 6.3;95% CI: 0.6, 8.9;P = .03)。

 

 散点图显示静脉血氧饱和度(SvO2)的动态变化与(A)最大超过6秒容积的时间(Tmax>6s)、(B)NIHSS的变化以及(C)治疗后消失的修正的Rankin量表(mRS)评分90天时的相关性。

总之,这项可行性研究表明,APCVs的动态变化可以反映急性缺血性卒中(AIS)后的氧利用和调节情况,AIS患者的脑静脉氧饱和度(SvO2)的改善与随访时APCVs消失患者的预后良好相呼应。尽管我们的研究样本在临床表现和治疗方面存在很大差异,但本研究可以一致地检测到整个APCVs区域内SvO2的增加,证明了使用QSM监测SvO2的现实可行性和适用性。

原文出处

Xiudi Lu,Yu Luo,Miller Fawaz,et al.Dynamic Changes of Asymmetric Cortical Veins Relate to Neurologic Prognosis in Acute Ischemic Stroke.DOI:10.1148/radiol.2021210201

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1720439, encodeId=1d5b1e20439f1, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Fri Jan 21 23:10:24 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010446, encodeId=491b2010446ff, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Jan 17 09:10:24 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893467, encodeId=b981189346e63, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Feb 08 14:10:24 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806493, encodeId=ad871806493b6, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Jul 26 02:10:24 CST 2022, time=2022-07-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1720439, encodeId=1d5b1e20439f1, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Fri Jan 21 23:10:24 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010446, encodeId=491b2010446ff, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Jan 17 09:10:24 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893467, encodeId=b981189346e63, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Feb 08 14:10:24 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806493, encodeId=ad871806493b6, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Jul 26 02:10:24 CST 2022, time=2022-07-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1720439, encodeId=1d5b1e20439f1, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Fri Jan 21 23:10:24 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010446, encodeId=491b2010446ff, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Jan 17 09:10:24 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893467, encodeId=b981189346e63, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Feb 08 14:10:24 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806493, encodeId=ad871806493b6, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Jul 26 02:10:24 CST 2022, time=2022-07-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1720439, encodeId=1d5b1e20439f1, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Fri Jan 21 23:10:24 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010446, encodeId=491b2010446ff, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Jan 17 09:10:24 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893467, encodeId=b981189346e63, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Feb 08 14:10:24 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806493, encodeId=ad871806493b6, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Jul 26 02:10:24 CST 2022, time=2022-07-26, status=1, ipAttribution=)]

相关资讯

JNNP:急性功能性假性卒中与轻度急性缺血性卒中的长期随访比较

每年都有许多患者因怀疑患有急性缺血性中风(AIS)而入住急诊室。有几种情况可以表现为急性中风样症状,其中最常见的是癫痫发作、偏头痛和功能紊乱。后者被称为假性功能性中风(FSM)。虽然AIS患者的预后已

JAHA:血红蛋白浓度与急性缺血性卒中或TIA患者临床结局之间的关系

异常的血红蛋白浓度与更高的全因死亡、不良功能结局、卒中复发和复合血管事件风险相关。该研究的结果表明需要更多设计良好的临床研究来证实血红蛋白浓度与卒中后患者临床结局之间的关系。

Neurology:不用RAPID,不用MR,也能识别发病4.5h内的患者

本研究为回顾性多中心研究,采用 CT低灌注-低密度错配识别发病4.5小时内的卒中患者。研究对象为急性缺血性卒中并且已知发病时间的患者。主要结局指标为:CT低灌注-低密度错配识别发病4.5小时内的预测值

阿加曲班治疗急性缺血性卒中中国专家共识指南2021

目前针对AIS发病早期抗凝治疗的随机对照研究显示,多数抗凝药物虽在一定程度上可降低卒中复发率或减少深静脉血栓形成的风险,但同时会增加出血事件的风险。

Stroke:急性缺血性卒中患者内源性脱氧核糖核酸酶活性和无细胞脱氧核糖核酸的临床意义

急性卒中内源性脱氧核糖核酸酶活性和cfDNA的相互作用需要有趣的新诊断和潜在治疗方法。研究人员确认cfDNA与大血管闭塞导致的卒中有害临床过程存在独立关联。

Lancet Neurol:难分伯仲——非免疫原性重组葡激酶与阿尔替普酶治疗急性缺血性卒中患者的比较(FRIDA)

对于急性缺血性卒中患者,非免疫原性葡激酶的疗效不逊于阿尔替普酶。病死率、症状性颅内出血和严重不良事件在各组之间没有显著差异,其在4.5h时间窗内治疗急性缺血性卒中的安全性和有效性有待进一步研究。

Baidu
map
Baidu
map
Baidu
map